Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Daiichi Sankyo
Daiichi Sankyo
AstraZeneca, Daiichi Sankyo tease new Enhertu data — but details remain under wraps
Endpoints
Mon, 03/6/23 - 11:27 pm
AstraZeneca
Daiichi Sankyo
Enhertu
clinical trials
Daiichi Sankyo gets US patent office to restart review of Seagen patent
Endpoints
Mon, 02/20/23 - 12:40 pm
Daiichi Sankyo
Seagen
PTO
patents
Daiichi Sankyo to build Japan's first mRNA vaccine manufacturing facility — report
Endpoints
Wed, 02/8/23 - 10:58 pm
Daiichi Sankyo
Japan
MRNA
vaccines
drug manufacturing
The first big test for the son of Enhertu
EP Vantage
Fri, 01/20/23 - 10:17 am
Daiichi Sankyo
Enhertu
datopotamab deruxtecan
clinical trials
Biopharma's stock market winners of 2022 revealed
EP Vantage
Wed, 01/18/23 - 09:46 am
pharma stocks
Merck
Eli Lilly
AbbVie
Daiichi Sankyo
Vertex Pharmaceuticals
Takeda
Sarepta Therapeutics
Halozyme
Horizon Therapeutics
10 clinical trials to watch in the first half of 2023
BioPharma Dive
Tue, 01/3/23 - 10:57 am
clinical trials
Alzheimer's disease
obesity
Huntington's disease
M&A
AstraZeneca
Daiichi Sankyo
Nimbus Therapeutics
Takeda
Eli Lilly
Sanofi
Regeneron
Moderna Therapeutics
Gilead Sciences
Pfizer
Roivant
Alnylam
uniQure
Biotech’s key upcoming clinical results
EP Vantage
Tue, 12/20/22 - 10:27 am
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
Big pharma’s new year catalysts
EP Vantage
Mon, 12/19/22 - 11:05 am
AstraZeneca
Daiichi Sankyo
Pfizer
Roche
CSL
uniQure
Novo Nordisk
Eli Lilly
AstraZeneca-Daiichi Sankyo’s therapy shows response in breast cancer trials
Clinical Trials Arena
Mon, 12/12/22 - 10:26 am
AstraZeneca
Daiichi Sankyo
clinical trials
datopotamab deruxtecan
metastatic triple-negative breast cancer
breast cancer
SABCS: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla
Fierce Pharma
Fri, 12/9/22 - 10:54 am
SABCS
AstraZeneca
Enhertu
breast cancer
Daiichi Sankyo
Roche
Kadcyla
Chasing Gilead, AstraZeneca-Daiichi lay down phase 2 breast cancer data for antibody-drug conjugate
Fierce Biotech
Fri, 12/9/22 - 10:46 am
AstraZeneca
Daiichi Sankyo
breast cancer
antibody-drug conjugate
clinical trials
Gilead Sciences
Daiichi Sankyo To Transfer Yescarta Marketing Authorization In Japan To Gilead Sciences
NASDAQ.com
Thu, 12/8/22 - 10:03 am
Daiichi Sankyo
Gilead Sciences
Yescarta
Japan
The problem with Her2-low testing
EP Vantage
Mon, 11/28/22 - 07:34 pm
AstraZeneca
Daiichi Sankyo
Enhertu
breast cancer
diagnostics
HER2-low breast cancer
Cancer drugmaker Plexxikon gets new life as Opna Bio
BioPharma Dive
Tue, 11/22/22 - 10:38 am
Plexxikon
Opna Bio
rebranding
oncology
Daiichi Sankyo
Daiichi Sankyo’s Covid-19 vaccine trial meets primary endpoint
Clinical Trials Arena
Tue, 11/15/22 - 10:51 am
Daiichi Sankyo
clinical trials
MRNA
vaccines
DS-5670
COVID-19
After nearly 20 years, Cyclacel kicks phase 3 leukemia drug back to Daiichi
Fierce Biotech
Thu, 11/10/22 - 10:39 am
Cyclacel
AML
Sapacitabine
Daiichi Sankyo
Daiichi Sankyo sets new highs for AstraZeneca-partnered cancer drug Enhertu
Endpoints
Mon, 10/31/22 - 04:15 pm
Daiichi Sankyo
AstraZeneca
Enhertu
breast cancer
non-small cell lung cancer
FDA grants priority review for Daiichi Sankyo’s AML medicine
Pharmaceutical Business Review
Tue, 10/25/22 - 10:37 am
FDA
priority review
Daiichi Sankyo
quizartinib
acute myeloid leukemia
Few safe havens surface in another down quarter for biopharma
EP Vantage
Fri, 10/14/22 - 10:03 am
biopharma stocks
COVID-19
Eli Lilly
Bristol Myers Squibb
Merck
Daiichi Sankyo
Vertex Pharmaceuticals
Takeda
Neurocrine
Sarepta Therapeutics
Orion
Pfizer
GSK
Roche
Moderna Therapeutics
BeiGene
BioNTech
Novavax
CureVac
The gloom deepens for biopharma stocks
EP Vantage
Mon, 10/10/22 - 06:54 pm
biopharma stocks
AbbVie
Alnylam
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eisai
Eli Lilly
GSK
Intellia Therapeutics
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »